

## Retraction: Obatoclox Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells *In Vitro* and *In Vivo*

Girija Dasmahapatra, Dmitry Lembersky, Minkyong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, and Steven Grant



This article (1) has been retracted at the request of the editors. The AACR Publications Department was notified that the U.S. Department of Health and Human Services' Office of Research Integrity determined that Girija Dasmahapatra, the first author of the above-mentioned article, engaged in research misconduct by falsifying and/or fabricating data that appeared in the 2012 article (2). Specifically, respondent reused, and/or relabeled Western blot panels and mouse images and claimed they represented different controls and/or experimental results in: Figs. 3A (JNK and Tubulin), 3B (Tubulin—scram), 3D (Tubulin—pUSE-AKT cl.3), and 6B (CFZ + obato; ref. 2). The matter was reviewed by members of the AACR Publications staff and the MCT editors, who agree that the figure manipulation present in the article merits retraction.

A copy of this Retraction Notice was sent to the last known email addresses for all 10 of the authors. 5 authors (E. Attkisson, R.I. Fisher, J.W. Friedberg, P. Dent, and S. Grant) agreed to the retraction; 4 authors (D. Lembersky, M.P. Son, H. Patel, D. Peterson) did not respond; and 1 author (G. Dasmahapatra) could not be located.

### References

1. Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, et al. Obatoclox interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells *in vitro* and *in vivo*. *Mol Cancer Ther* 2012;11:1122–32.
2. Findings of research misconduct. *Federal Register* 2015;80:76703–4.

Published online June 3, 2019.  
*Mol Cancer Ther* 2019;18:1180  
doi: 10.1158/1535-7163.MCT-19-0470  
©2019 American Association for Cancer Research.